Novato
NOVATO, California, October 18, 2010 - Sonic Solutions(R) (Nasdaq: SNIC) today announced the successful
integration of MainConcept, the world's leading producer of video and audio
codec software development kits (SDKs), into Sonic's new Professional
Technology Division.
NOVATO, California and SAN DIEGO, June 2, 2010 - Sonic Solutions(R) (Nasdaq: SNIC) and DivX, Inc.
NOVATO, California, February 10 - Raptor Pharmaceutical Corp.
NOVATO, California, January 11 - Raptor Pharmaceutical Corp.
NOVATO, California, December 23 - Raptor Pharmaceutical Corp.
More News
- Raptor Pharmaceutical Corp. Announces US$7.5 Million Securities Offering
- Raptor Pharmaceutical Corp. Announces Positive Data on NGX426 in the Potential Treatment of Neuropathic Pain
- Goal of Trial Achieved Demonstrating Potentially Less Frequent Administration Using Lower Daily Dose
- Raptor Pharmaceutical Corporation Announces Presentation of Data for NGX426, a Novel, Non-Opioid Oral Analgesic, at Neuropathic Pain Conference
- Raptor Pharmaceutical Corp. to Present at the 8th Annual BIO Investor Forum
- Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non-Alcoholic Steatohepatitis (NASH)
- Raptor Pharmaceutical Expands Board of Directors
- Raptor Pharmaceuticals Corp. and TorreyPines Complete Merger
- Raptor Pharmaceuticals and TorreyPines Therapeutics Receive Stockholder Approvals to Merge
- Raptor Pharmaceuticals Raises US$5 Million
- Raptor Pharmaceuticals Corp. and TorreyPines Therapeutics, Inc. Announce Merger Agreement
- Raptor Pharmaceuticals to Collaborate with Roche on Therapeutic Delivery Across Blood-Brain Barrier
- Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis
- Raptor Pharmaceuticals Receives Notices of Allowance for Two NeuroTrans(TM) Patent Applications
- BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
- Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer
